Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Juno Therapeutics Inc (JUNO), Anacor Pharmaceuticals Inc (ANAC): VHCP Management’s Top 3 Biotech Picks

Page 1 of 2

Andres Hove and Bong Koh’s VHCP Management revealed its top 3 biotech picks heading into 2015, in a 13F Form filed with the U.S. Securities and Exchange Commission last month. While Juno Therapeutics Inc (NASDAQ:JUNO) was the largest position in the hedge fund’s equity portfolio at the end of the year, the investment firm was also betting big on Avalanche Biotechnologies Inc (NASDAQ:AAVL) and Anacor Pharmaceuticals Inc (NASDAQ:ANAC).Avalanche Biotechnologies Inc (NASDAQ:AAVL)

Venrock Healthcare Capital Partners, L.P. was originally founded in 1969 by Laurence S. Rockefeller, as the venture capital branch of the Rockefeller family. The investment firm has always been engaged in the technology sector, while placing its focus on the healthcare industry and biotechnology sector in recent years. As it tends to invest in early-stage companies and start-ups, VHCP Management continues to establish partnerships with entrepreneurs in order to create successful and long-lasting businesses.  The fund has been very successful in its ventures, landing big wins by supporting publicly traded equities such as Apple Inc (NASDAQ:AAPL), Intel Corporation (NASDAQ:INTC), and Gilead Sciences, Inc. (NASDAQ:GILD).

Juno Therapeutics Inc (NASDAQ:JUNO) was VHCP Management’s top pick at the end of the last quarter, accounting for more than 20% of its equity portfolio. The fund only began betting on the company recently, as the position in Juno is a new one opened during the fourth quarter, which amounts to approximately 1.75 million shares. Following this acquisition, VHCP Management has become the largest institutional investor betting on the stock amongst the funds we track. Another fund taking a bullish stance towards Juno Therapeutics Inc (NASDAQ:JUNO) last quarter was Peter Kolchinsky’s RA Capital Management, which owned 280,000 shares. Guy Shahar’s DSAM Partners also entered a position in the company last quarter, disclosing a stake of 103,500 shares.

VHCP Management’s top pick is already delivering hefty returns, as the stock has gained more than 30% since its IPO in December. According to Zacks Investment Research, brokerages have set a twelve-month consensus price target of $67.67 per share, a premium of nearly 50% on the current trading rate of shares, meaning the fund could see returns rise even higher in 2015. Juno Therapeutics is a Seattle-based biopharmaceutical company that is focused on the development of cell-based cancer immunotherapies.

VHCP Management has been betting on Avalanche Biotechnologies Inc (NASDAQ:AAVL) since August of 2014, when it acquired a new stake of 4.33 million shares, though it quickly reduced its stake to just 1.38 million shares by the end of September. According to its latest 13F filing, the fund still owns 1.38 million shares, unchanged during the previous quarter. James E. Flynn’s Deerfield Management is also backing the company, which ranks amongst its top picks, with a stake of 1.61 million shares in its last 13F filing. Although the stock has gained more than 30% since it began trading in August, shares are down by 31% year-to-date. Nevertheless, numerous Wall Street analysts seem optimistic regarding the company, which was rated as a “strong buy” by the brokers at Zacks.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!